WHO Biowaiver Study Project for COVID-19 Outbreak: Dexamethasone Solubility Results for Biopharmaceutical Classification System.

Item request has been placed!

Item request cannot be made.

Processing Request

Read More Get Citations

Additional Information
- Subject Terms:
  BIOAVAILABILITY; INTRAVENOUS therapy; MOLECULAR structure; ORAL medication; WORLD Health Organization; DEXAMETHASONE; COVID-19; COVID-19 pandemic
- Abstract:
  The article offers information on the WHO Biowaiver Study Project for Covid-19 test with the use of Dexamethasone solubility. It discusses that the Dexamethasone solubility was studied at the therapeutic dose of 6 mg, which is the same dosage used in the COVID-19 Recovery Trial7 and currently recommended in adults and adolescents over 12 years of age (weighing more than 40 kg) 2,8 for the treatment of patients with severe and critical COVID-19.